SCHEMBL19743929

SCHEMBL19743929

CSc1cnc(N)c(C(=O)O)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
GRM5 P41594 3/20 0.36
ATR Q13535 8/20 0.36
PLAU P00749 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
PRKDC P78527 2/20 0.34
KDM6B O15054 1/20 0.33
KDM4A O75164 1/20 0.33
KDM4D Q6B0I6 1/20 0.33
HIF1AN Q9NWT6 1/20 0.33
KDM2A Q9Y2K7 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3575758 0.76 GRM5 (0.53) MEN1KMT2AKDM4EALDH1A1GRM5
SCHEMBL10256130 0.75 PLAU (0.46) KMT2AKDM4EALDH1A1ATRPLAU
SCHEMBL410727 0.73 ATR (0.58) KMT2AKDM4EALDH1A1GRM5ATR
SCHEMBL12186472 0.72 ATR (0.38) ALDH1A1ATRTDP1PRKDCGABRP
SCHEMBL1318334 0.72 GRM5 (0.51) MEN1KMT2AALDH1A1GRM5ATR
SCHEMBL2114667 0.72 ATR (0.38) ALDH1A1ATRTDP1PRKDCGABRP
SCHEMBL3868054 0.71 GABRP (0.41) MEN1KMT2AGRM5ATRTDP1
SCHEMBL13242155 0.71 GRM5 (0.42) MEN1KMT2AKDM4EGRM5ATR
SCHEMBL4253183 0.71 SIRT6 (0.47) KDM4EALDH1A1LMNAATRPLAU
SCHEMBL13346098 0.71 ATR (0.36) MEN1KMT2AKDM4EGRM5ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759785-B2 Compounds Enterprise Therapeutics Limited (GB) 2020-09-01 US disclosed
US-10759785-B2 Compounds Enterprise Therapeutics Limited (GB) 2020-09-01 US disclosed
EP-3472154-B1 COMPOUNDS ENTERPRISE THERAPEUTICS LTD (GB) 2020-08-12 EP disclosed
EP-3472154-B1 COMPOUNDS ENTERPRISE THERAPEUTICS LTD (GB) 2020-08-12 EP disclosed
US-20190233402-A1 COMPOUNDS Enterprise Therapeutics Limited (GB) 2019-08-01 US disclosed
US-20190233402-A1 COMPOUNDS Enterprise Therapeutics Limited (GB) 2019-08-01 US disclosed
EP-3472154-A1 COMPOUNDS Enterprise Therapeutics Limited (GB) 2019-04-24 EP disclosed
WO-2017221008-A1 COMPOUNDS Enterprise Therapeutics Limited (GB) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190233402-A1 COMPOUNDS CFTR, NHERF1, SCNN1A MEN1 1141/4885KMT2A 4232/4885KDM4E 4220/4885
US-10759785-B2 Compounds CFTR, NHERF1, SCNN1A MEN1 1141/4885KMT2A 4232/4885KDM4E 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.